You just read:

Health Canada approves Pradaxa® for the treatment of venous thromboembolism events (deep vein thrombosis [DVT] and pulmonary embolism [PE]), and for the prevention of recurrent DVT and PE(1)

News provided by

Boehringer Ingelheim (Canada) Ltd.

Sep 04, 2014, 08:00 ET